Patents by Inventor Brian M. Fox

Brian M. Fox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATORS OF EUKARYOTIC INITIATION FACTOR 2
    Publication number: 20240140919
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators of formula A, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof and methods of making and using thereof.
    Type: Application
    Filed: December 1, 2023
    Publication date: May 2, 2024
    Inventors: Robert A. Craig II, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Katrina W. Lexa, Maksim Osipov, Zachary K. Sweeney, Arun Tottumkara
  • Compounds, compositions and methods
    Patent number: 11958840
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: March 23, 2022
    Date of Patent: April 16, 2024
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Maksim Osipov, Arun Thottumkara
  • SOLID FORMS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL)-3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILE
    Publication number: 20240025915
    Abstract: Described herein are solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2H-pyrido[3,4-f][1,4]oxazepine-9-carbonitrile, the process of preparing the forms, pharmaceutical compositions comprising same, and methods of use thereof.
    Type: Application
    Filed: July 24, 2023
    Publication date: January 25, 2024
    Applicant: Denali Therapeutics Inc.
    Inventors: Javier de Vicente Fidalgo, Brian M. Fox, Christopher R.H. Hale
  • COMPOUNDS, COMPOSITIONS, AND METHODS
    Publication number: 20230416205
    Abstract: The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NL-RP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.
    Type: Application
    Filed: November 19, 2021
    Publication date: December 28, 2023
    Inventors: Alex L. Bagdasarian, Cyril Bucher, Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Brian M. Fox, Cheng Hu, Benjamin J. Huffman, Katrina W. Lexa, Lizanne G. Nilewski, Maksim Osipov, Arun Thottumkara
  • Modulators of eukaryotic initiation factor 2B, compositions and methods
    Patent number: 11851440
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: December 26, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R. H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20230357162
    Abstract: The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NL-RP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.
    Type: Application
    Filed: August 13, 2021
    Publication date: November 9, 2023
    Inventors: Alex L. Bagdasarian, Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Brian M. Fox, Cheng Hu, Benjamin J. Huffman, Katrina W. Lexa, Lizanne G. Nilewski, Maksim Osipov, Arun Thottumkara
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20230348437
    Abstract: The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NL-RP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.
    Type: Application
    Filed: July 1, 2021
    Publication date: November 2, 2023
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Brian M. Fox, Cheng Hu, Katrina W. Lexa, Lizanne G. Nilewski, Maksim Osipov, Arun Thottumkara
  • PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR
    Publication number: 20230301974
    Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
    Type: Application
    Filed: May 8, 2023
    Publication date: September 28, 2023
    Applicant: AMGEN INC.
    Inventors: Matthew BIO, Sebastien CAILLE, Brian COCHRAN, Yuanqing FANG, Brian M. FOX, Brian S. LUCAS, Lawrence R. MCGEE, Filisaty VOUNATSOS, Sean H. WIEDEMANN, Sarah WORTMAN
  • MODULATORS OF EUKARYOTIC INITIATION FACTOR 2
    Publication number: 20230250072
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators of formula A, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof and methods of making and using thereof.
    Type: Application
    Filed: April 14, 2023
    Publication date: August 10, 2023
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Katrina W. Lexa, Maksim Osipov, Zachary K. Sweeney, Arun Thottumkara
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20230114472
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Application
    Filed: March 23, 2022
    Publication date: April 13, 2023
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Maksim Osipov, Arun Thottumkara
  • Modulators of eukaryotic initiation factor 2B, compositions and methods
    Publication number: 20220411433
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
    Type: Application
    Filed: November 19, 2021
    Publication date: December 29, 2022
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R.H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney
  • PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR
    Publication number: 20220280496
    Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
    Type: Application
    Filed: October 13, 2021
    Publication date: September 8, 2022
    Applicant: AMGEN INC.
    Inventors: Matthew BIO, Sebastien CAILLE, Brian COCHRAN, Yuanqing FANG, Brian M. FOX, Brian S. LUCAS, Lawrence R. MCGEE, Filisaty VOUNATSOS, Sean H. WIEDEMANN, Sarah WORTMAN
  • CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
    Patent number: 11407721
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: August 9, 2022
    Assignee: AMGEN INC.
    Inventors: Michael D. Bartberger, Hilary Plake Beck, Michael R. Degraffenreid, Brian M. Fox, Felix Gonzalez Lopez De Turiso, Lisa D. Julian, Frank Kayser, Julio C. Medina, Steven H. Olson, Yosup Rew, Philip M. Roveto, Daqing Sun, Xuelei Yan
  • Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer
    Publication number: 20220169611
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: February 15, 2022
    Publication date: June 2, 2022
    Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Dequette, I, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua Ma, Lawrence R. McGee, Josel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yossup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
  • Compounds, compositions and methods
    Patent number: 11306077
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: April 19, 2022
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Maksim Osipov, Arun Thottumkara
  • Modulators of eukaryotic initiation factor 2B, compositions and methods
    Patent number: 11236100
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: February 1, 2022
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R. H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20210292311
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Application
    Filed: May 28, 2021
    Publication date: September 23, 2021
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Maksim Osipov, Arun Thottumkara
  • Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer
    Publication number: 20210179560
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: August 3, 2020
    Publication date: June 17, 2021
    Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, I, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua MA, Lawrence R. McGee, Joel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yossup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20210147435
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
    Type: Application
    Filed: August 8, 2018
    Publication date: May 20, 2021
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R.H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney
  • MODULATORS OF EUKARYOTIC INITIATION FACTOR 2
    Publication number: 20210130308
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators of formula A, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof and methods of making and using thereof.
    Type: Application
    Filed: March 22, 2019
    Publication date: May 6, 2021
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Katrina W. Lexa, Maksim Osipov, Zachary K. Sweeney, Arun Thottumkara